Loading clinical trials...
Loading clinical trials...
Effects of Intravenous Delivery of Lomecel-B (Formerly Allogenic Longeveron Human Mesenchymal Stem Cells (LMSCs)) on VaccinE-Specific Antibody Responses in Subjects With Aging Frailty
Conditions
Interventions
Longeveron Mesenchymal Stem Cells (LMSCs)
Fluzone High Dose Vaccine
Locations
6
United States
Clinical Research of South Florida
Coral Gables, Florida, United States
Clinical Physiology Associates
Fort Myers, Florida, United States
University of Miami
Miami, Florida, United States
Vista Health Research
Miami, Florida, United States
Johns Hopkins University
Baltimore, Maryland, United States
Optimal Research LLC
Rockville, Maryland, United States
Start Date
November 1, 2016
Primary Completion Date
September 1, 2021
Completion Date
September 1, 2022
Last Updated
November 4, 2022
Lead Sponsor
Longeveron Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions